Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New depression pill shows promise in early trial

NCT ID NCT06836063

Symptom relief Sponsor: Suven Life Sciences Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2b trial tested whether ropanicant, an experimental drug taken twice daily, can reduce symptoms of major depressive disorder. 214 adults with moderate to severe depression received either ropanicant or a placebo for 6 weeks. The main goal was to see if the drug improved depression scores on a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropanicant (also known as SUVN-911)
What this could lead to
If successful, ropanicant could offer a new oral medication option for people with major depressive disorder.
What could go wrong
This is an early-phase (2b) trial with only 214 participants. The drug may not prove more effective than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

214 people

The number who actually took part.

Started

Jul 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MDD without psychotic features based on the Mini International Neuropsychiatric Interview (MINI) with a current major depressive episode of at least 4 weeks of duration but no longer than 12 months. * Patients must have a Clinical Global Impression-Severity (CGI-S) score of ≥4. * Patients must have a Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D) score of ≥20. * Patients must have a Snaith-Hamilton Pleasure Scale (SHAPS) score of ≥20. * Patients must have vision and hearing (corrected if needed) sufficient to comply with the testing procedures. Exclusion Criteria: * Patients who meet criteria for treatment-resistant depression (TRD) during the current major depressive episode, which is defined as being nonresponders (\<50% of symptom improvement) to 2 or more depression treatment periods of adequate dose and duration. * Patients not in good general health with clinically significant abnormalities as assessed by the investigator and determined by physical examination results, neurological examination results, ECG results, or laboratory assessments. * Female patients who are pregnant, planning to become pregnant during the study or within 30 days after the last administration of study drug, or breastfeeding. * Patients with bradycardia (\<50 bpm) or tachycardia (\>100 bpm) on the ECG results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

Contacts and locations

Locations

  • ATP Clinical Research

    Orange, California, 92866, United States

  • Advanced Research Center, Inc.

    Anaheim, California, 92805, United States

  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331, United States

  • Behavioral Research Specialists, LLC

    Glendale, California, 91206, United States

  • CenExcel iResearch LLC

    Decatur, Georgia, 30030, United States

  • CenExcel iResearch LLC

    Savannah, Georgia, 31405, United States

  • Center for Emotional Fitness

    Cherry Hill, New Jersey, 08002, United States

  • Chicago Research Center Inc.

    Chicago, Illinois, 60634, United States

  • Clinical Neuroscience Solutions Inc.

    Memphis, Tennessee, 38119, United States

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32256, United States

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801, United States

  • Collaborative Neuroscience Research

    Torrance, California, 90504, United States

  • Community Clinical Research, Inc.

    Austin, Texas, 78754, United States

  • Core Clinical Research

    Everett, Washington, 98201, United States

  • Excell Research, Inc.

    Oceanside, California, 92056, United States

  • Eximia Research-NC, LLC

    Raleigh, North Carolina, 27607, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613, United States

  • Hassman Research Institue

    Marlton, New Jersey, 08053, United States

  • Memorial Hermann Village

    Houston, Texas, 77043, United States

  • Midwest Research Group

    Saint Charles, Missouri, 63304, United States

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan, 48302, United States

  • Neurobehavioral Research Inc.

    Cedarhurst, New York, 11516, United States

  • North Texas Clinical Trials, LLC

    Fort Worth, Texas, 76104, United States

  • Panhandle Research and Medical Clinic LLC

    Pensacola, Florida, 32503, United States

  • Precise Research Centers

    Flowood, Mississippi, 39232, United States

  • Premier Clinical Research Institute, Inc

    Miami, Florida, 33122, United States

  • ProScience Research Group

    Culver City, California, 90230, United States

  • Redbird Research, LLC

    Las Vegas, Nevada, 89119, United States

  • Richmond Behavioral Associates

    Staten Island, New York, 10312, United States

  • SPRI Clinical Trials, LLC

    Brooklyn, New York, 11235, United States

  • Sooner Clinical Research, Inc

    Oklahoma City, Oklahoma, 73116, United States

  • Synergy San Diego

    Lemon Grove, California, 91945, United States

  • Vector Clinical Trials

    Las Vegas, Nevada, 89128, United States

  • Woodland International Research Group LLC

    Little Rock, Arkansas, 72211, United States

  • Woodland Research Northwest

    Rogers, Arkansas, 72758, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.